Madrigal Pharma (NASDAQ: MDGL) reported Q2 EPS of ($7.10), $0.38 better than the analyst estimate of ($7.48). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $4.25 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.